$SGHT

Analysts initiated coverage on several companies: Piper Sandler rated Redwire Corp (RDW) Neutral with a $11 target, Cantor Fitzgerald rated Eloxx Pharmaceuticals (ELOX) Overweight, HC Wainwright rated Sight Sciences (SGHT) Buy with a $14 target, Goldman Sachs rated Anglogold Ashanti (AU) Buy with a $104 target, and Raymond James rated First Financial Bankshares (FFIN) Market Perform.

Sight Sciences (SGHT) launched the OMNI Ultra MIGS System, an implant-free device, at AAO 2026. The company aims to extend its OMNI platform in the MIGS category, with future success depending on surgeon adoption and reimbursement support, according to AI Analyst.

Sight Sciences (SGHT) announced the launch of the OMNI Ultra Surgical System, an advanced glaucoma treatment. The system will be showcased at the 2026 American Academy of Ophthalmology annual meeting. OMNI Ultra is designed to reduce intraocular pressure by addressing key areas of resistance in the eye's aqueous outflow pathway.

Several biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.

Sight Sciences (SGHT) announced FDA expanded the TearCare System's use to improve meibomian gland function in adults with evaporative dry eye disease due to MGD. This makes TearCare the first treatment indicated for this purpose, according to the company. The update also includes optional debridement, enhancing its approach to treating the condition. SGHT reported Q2 2026 revenue growth and updated its full-year guidance earlier this month.

Sight Sciences (SGHT) announced FDA approval for its TearCare System to improve meibomian gland function in patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD). This makes TearCare the first and only treatment indicated for this purpose, expanding its market potential. The company's CEO and a medical expert highlighted the significance of this milestone in dry eye disease treatment.

Sight Sciences (SGHT) reported Q2 2026 revenue of $23.4M, up 20% y/y, driven by Interventional Glaucoma ($20.7M) and Interventional Dry Eye ($2.7M). Gross margin rose to 91% from 85%. Net loss was $4.4M. FY2026 revenue guidance raised to $88M-$92M; adjusted opex guidance lowered to $92M-$94M. Alcon patent appeal remains pending.

Sight Sciences, Inc. (SGHT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of Chief Legal Officer On August 6, 2026, the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Com

Biotech gainers included Creative Medical (CELZ), up 71.95% after a new U.S. patent for exosome-based immunotherapy for Type 1 diabetes. Braveheart Bio (BRVE) jumped 65.56% on its Nasdaq debut. Iovance (IOVA) rose 43.09% after Q2 product revenue rose 66% to about $99M. Sight Sciences (SGHT) gained 27.75% after raising 2026 revenue guidance to $88M-$92M.

Sight Sciences, Inc. (SGHT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sight Sciences Reports Second Quarter 2026 Financial Results Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance MENLO PARK, Calif., August 5, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Compa